Last reviewed · How we verify
Sugar water
Sugar water, marketed by Baylor College of Medicine, holds a unique position in the pharmaceutical market despite lacking a defined mechanism or primary indication. The key composition patent is set to expire in 2028, providing a period of exclusivity that could be leveraged for market dominance. However, the lack of clear therapeutic benefits and revenue data poses a significant risk to its long-term commercial viability.
At a glance
| Generic name | Sugar water |
|---|---|
| Sponsor | Baylor College of Medicine |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Consumption of Oral Artificial Sweeteners on Platelet Aggregation and Polyol Excretion (NA)
- Effects of Different Caffeine Forms on Aerobic and Anaerobic Exercise Performance (NA)
- Assessments of Adipogenesis, Lipid Turnover and Cellular Composition in Adipose Tissue in Response to Endurance Exercise (NA)
- The Effect of Chewing Gum and Hot Compresses on Gynecologic Oncologic Surgery (NA)
- Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults (PHASE1)
- A Comparison of Satiety Effects Two Commercially Available Snack Bars (NA)
- To Determine the Effect of Phaseolean on Glycemic Response to Carbohydrate Rich Meal in Healthy Adult Human Participants (NA)
- Nutrition for Precision Health, Powered by the All of Us (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sugar water CI brief — competitive landscape report
- Sugar water updates RSS · CI watch RSS
- Baylor College of Medicine portfolio CI